Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer

  • G. RovielloEmail author
  • F. U. Conter
  • E. Mini
  • D. Generali
  • M. Traversini
  • D. Lavacchi
  • S. Nobili
  • N. Sobhani
Review Article


Gastric cancer (GC) is the third cause of cancer-related death worldwide. Patients with unresectable GC can be treated with chemotherapy such as paclitaxel, which is a microtubule stabilizer. The use of nanoparticle albumin-bound paclitaxel (nab-ptx) avoids hypersensitivity reactions due to the absence of solvent needed to dissolve paclitaxel and it can be administered at higher doses. The ABSOLUTE randomized phase-3 clinical trial showed the non-inferiority of the nab-ptx used every week compared to the solvent-based paclitaxel used every week. This review describes the current advancements of the use of nab-ptx in GC in preclinical and clinical study investigations. The possibility of combining nab-ptx with other medications to improve response of patients to their specific molecular needs will also be debated.


Paclitaxel Nanoparticle Nab-paclitaxel Ramucirumab 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRefGoogle Scholar
  2. 2.
    Yokoyama T (2011) Clinicopathological analysis for recurrence of stage Ib gastric cancer (according to the second English edition of the Japanese classification of gastric carcinoma). Gastric Cancer 14:372–377CrossRefGoogle Scholar
  3. 3.
    Ilson DH (2018) Advances in the treatment of gastric cancer. Curr Opin Gastroenterol 34:465–468CrossRefGoogle Scholar
  4. 4.
    Petrioli R, Roviello G, Zanotti L, Roviello F, Polom K, Bottini A, Marano L, Francini E, Marrelli D, Generali D (2016) Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol 102:82–88CrossRefGoogle Scholar
  5. 5.
    Petrioli R et al (2015) Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer Chemother Pharmacol 75(5):941–947CrossRefGoogle Scholar
  6. 6.
    Ford HER et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15:78–86CrossRefGoogle Scholar
  7. 7.
    Kang JH et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513–1518CrossRefGoogle Scholar
  8. 8.
    Thuss-Patience PC et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306–2314CrossRefGoogle Scholar
  9. 9.
    Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235CrossRefGoogle Scholar
  10. 10.
    Kang JH, Lee SI, do Lim H et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513–1518CrossRefGoogle Scholar
  11. 11.
    Roviello G, Ravelli A, Fiaschi AI et al (2016) Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol 10(8):887–892Google Scholar
  12. 12.
    Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471CrossRefGoogle Scholar
  13. 13.
    Shitara K, Doigf T, Dvorkin M et al (2018) Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19(11):1437–1448CrossRefGoogle Scholar
  14. 14.
    Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598CrossRefGoogle Scholar
  15. 15.
    Dorr RT (1994) Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 28:S11–S14CrossRefGoogle Scholar
  16. 16.
    Ibrahim NK et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044Google Scholar
  17. 17.
    Nyman DW et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785–7793CrossRefGoogle Scholar
  18. 18.
    Schneeweiss A, Seitz J, Smetanay K, Schuetz F, Jaeger D, Bachinger A, Zorn M, Sinn HP, Marmé F (2014) Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res 34(11):6609–6615Google Scholar
  19. 19.
    Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD (2015) SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res 21(21):4811–4818CrossRefGoogle Scholar
  20. 20.
    Schettini F, Giuliano M, De Placido S, Arpino G (2016) Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives. Cancer Treat Rev 50:129–141CrossRefGoogle Scholar
  21. 21.
    Desai N et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324CrossRefGoogle Scholar
  22. 22.
    Gardner ER et al (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200–4205CrossRefGoogle Scholar
  23. 23.
    Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE (2013) Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One 8:e58037CrossRefGoogle Scholar
  24. 24.
    Kinoshita J et al (2014) Comparative study of the antitumor activity of nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep 32:89–96CrossRefGoogle Scholar
  25. 25.
    Xiong J, Han S, Ding S, He J, Zhang H (2018) Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer. Oncol Rep 39:1396–1404Google Scholar
  26. 26.
    Awasthi N, Schwarz MA, Zhang C, Schwarz RE (2018) Augmentation of nab-paclitaxel chemotherapy response by mechanistically diverse antiangiogenic agents in preclinical gastric cancer models. Mol Cancer Ther 17:2353–2364CrossRefGoogle Scholar
  27. 27.
    Zhang C-Η, Awasthi N, Schwarz MA, Schwarz RE (2013) The dual PI3 K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. Int J Oncol 43:1627–1635CrossRefGoogle Scholar
  28. 28.
    Sasaki Y et al (2014) Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci 105:812–817CrossRefGoogle Scholar
  29. 29.
    Bando H et al (2018) A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer 91:86–91CrossRefGoogle Scholar
  30. 30.
    Katsaounis P et al (2017) Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the hellenic oncology research group. Ann Gastroenterol 31:65–70Google Scholar
  31. 31.
    Kanazawa Y et al (2017) Initial experience with nab-paclitaxel for patients with advanced gastric cancer: safety and efficacy. Anticancer Res 37:2715–2720CrossRefGoogle Scholar
  32. 32.
    Fukuchi M et al (2016) Efficacy of nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Anticancer Res 36:6699–6703CrossRefGoogle Scholar
  33. 33.
    Sato S et al (2018) A phase II study of tri-weekly low-dose nab-paclitaxel chemotherapy for patients with advanced gastric cancer. Anticancer Res 38:6911–6917CrossRefGoogle Scholar
  34. 34.
    Watson S et al (2019) Oxaliplatin, 5-fluorouracil and nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: a GERCOR phase II study (FOXAGAST). Eur J Cancer 107:46–52CrossRefGoogle Scholar
  35. 35.
    Shitara K et al (2017) Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2:277–287CrossRefGoogle Scholar
  36. 36.
    Takashima A et al (2019) Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Gastric Cancer 22:155–163CrossRefGoogle Scholar
  37. 37.
    Nakayama N et al (2017) A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Gastric Cancer 20:350–357CrossRefGoogle Scholar
  38. 38.
    Kawamoto Y et al (2017) Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. BMC Cancer 17:837CrossRefGoogle Scholar
  39. 39.
    Gradishar W, Tjulandin S, Davidson N et al (2005) Phase III trial of nanaoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803CrossRefGoogle Scholar
  40. 40.
    Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30(17):2055–2062CrossRefGoogle Scholar
  41. 41.
    Goldstein D, El-Maraghi RH, Hammel P et al (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 31(2):107Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Health SciencesUniversity of FlorenceFlorenceItaly
  2. 2.Laboratory of Cancer BiologyLutheran University of Brazil (ULBRA)CanoasBrazil
  3. 3.Department of Medicine, Surgery and Health SciencesUniversity of Trieste, Cattinara Teaching HospitalTriesteItaly
  4. 4.Breast Cancer Unit and Translational Research UnitASST CremonaCremonaItaly
  5. 5.School of Human Health SciencesUniversity of FlorenceFlorenceItaly

Personalised recommendations